From: The role of m6A methylation in osteosarcoma biological processes and its potential clinical value
Source | Non-tumor samples | Tumor samples | m6A regulators | Role in | Potential application | References |
---|---|---|---|---|---|---|
Publicly datasets | 17 | 306 | METTL3, KIAA1429, HNRNPA2B1, FTO, METTL14, YTHDF2 | Poor prognosis | Biomarker | [60] |
Tissue microarray | 65 | 120 | METTL3, KIAA1429, HNRNPA2B1, FTO, METTL14, YTHDF2 | Poor prognosis | Biomarker | [60] |
Publicly datasets | 80 | 80 | METTL3 and ALKBH5 | Poor prognosis | Biomarker | [61] |
Clinical samples | 70 | 70 | ALKBH5 | Poor prognosis Oncogene | Biomarker Therapeutic target | [54] |
Publicly datasets | 3 | 44 | WTAP | Poor prognosis Oncogene | Biomarker Therapeutic target | [55] |
Clinical samples | 104 | 104 | WTAP | Poor prognosis Oncogene | Biomarker Therapeutic target | [55] |
Tissue microarray | 65 | 120 | KIAA1429 | Poor prognosis Chemotherapy resistance | Biomarker Therapeutic target | [56] |
Tissue microarray | 65 | 120 | YTHDF2 | Chemotherapy resistance | Therapeutic target | [57] |